Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances
Confirms Trial Weighted Towards Overall Survival Endpoint
Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.
You may also be interested in...
CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.
The Swiss drug maker is preparing for a smooth transition in 2023, appointing 20-year Roche veteran and diagnostic chief Thomas Schinecker as its next chief executive as Severin Schwan becomes chairman.
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.